Onchocerciasis

28 registered clinical trials studyying Onchocerciasis — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by F NCT07506967	Kenya Medical Research Institute	N/A
Not Yet Recruiting	Integrating Mental Health Into Neglected Tropical Disease Care in Ghana NCT07248462	Liverpool School of Tropical Medicine	N/A
Recruiting	Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected NCT07145736	Kirby Institute	Phase 4
Recruiting	Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination NCT06350851	Bioaster	N/A
Active Not Recruiting	Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis NCT06070116	Washington University School of Medicine	Phase 2
Withdrawn	Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa NCT04035174	Center for Research on Filariasis and Other Tropical Diseases, Cameroon	N/A
Terminated	Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug NCT05084560	Liverpool School of Tropical Medicine	Phase 1
Active Not Recruiting	Emodepside Phase II Trial for Treatment of Onchocerciasis NCT05180461	Drugs for Neglected Diseases	Phase 2
Terminated	Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or NCT04913610	AbbVie	Phase 2
Completed	Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic NCT04311671	Medicines Development for Global Health	Phase 3
Active Not Recruiting	Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis NCT03876262	Medicines Development for Global Health	Phase 3
Completed	A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 NCT03962062	Medicines Development for Global Health	Phase 1
Completed	Safety and Efficacy of IDA for Onchocerciasis NCT04188301	Washington University School of Medicine	Phase 2
Completed	Ocular Changes After Ivermectin - (DOLF IVM/Oncho) NCT03517462	Washington University School of Medicine	N/A
Completed	Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan NCT05750043	Universiteit Antwerpen	—
Completed	Prevalence of LF Infection in Districts Not Included in LF Control Activities NCT03131401	Noguchi Memorial Institute for Medical Research	—
Completed	Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy NCT03052998	Robert Colebunders	Phase 4
Completed	Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area NCT05749653	Universiteit Antwerpen	N/A
Unknown	Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District NCT03653975	Heidelberg University	—
Completed	Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana NCT02078024	University Hospitals Cleveland Medical Center	Phase 3
Completed	Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocercias NCT02032043	Washington University School of Medicine	—
Completed	IVM Alone vs ALB + IVM Against Onchocerciasis NCT03238131	University Hospitals Cleveland Medical Center	Phase 3
Completed	Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia NCT01905436	Washington University School of Medicine	—
Withdrawn	Pediatric Pharmacokinetics And Safety Study Of Moxidectin NCT01035619	Pfizer	Phase 2
Completed	Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection NCT00790998	Medicines Development for Global Health	Phase 3
Completed	Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection NCT00300768	Medicines Development for Global Health	Phase 2
Completed	Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness NCT00127504	Centers for Disease Control and Prevention	Phase 2
Recruiting	Host Response to Infection and Treatment in Filarial Diseases NCT00001230	National Institute of Allergy and Infectious Diseases (NIAID)	—